We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Shares of Stoke Therapeutics sank Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping down from his role.

Stoke Therapeutics, Inc. (NASDAQ:STOK) shares dropped 4.1% after the biotechnology company announced its CEO Edward M. Kaye will step down, overshadowing better-than-expected fourth quarter results.

Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers ...

In a surprise move, the longtime CEO of Stoke Therapeutics is leaving the company, weeks before the Phase 3 trial of its lead ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

Biogen, Cisco, IDEXX Laboratories and Waters Corporation entered into a new aggregated procurement under the Net Zero ...

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...